Refractory B-Cell Prolymphocytic Leukemia
2 clinical trials · Condition
◉ Watch Refractory B-Cell Prolymphocytic Leukemia
| Record | Firm | Date |
|---|---|---|
| Genetically Engineered Cells (Anti-CD19/CD20/CD22 CAR T-cells) for the Treatment of Relapsed or Refractory Lymphoid Malignancies (NCT05418088) | Sumithira Vasu | 2022-06-30 |
| Lenalidomide and Ibrutinib in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma (NCT01886859) | National Cancer Institute (NCI) | 2013-04-26 |
Track Refractory B-Cell Prolymphocytic Leukemia automatically
Every clearance here is in the API, with alerts when new ones post.